Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 268 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Results available

Transmagnetic Stimulation Pilot in Primary Progressive Aphasia

NCT05860647
Conditions
Primary Progressive Aphasia
Interventions
Intermittent theta burst stimulation
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Enrolling by invitation Phase 2 Interventional

Alzheimer's Tau Platform: Regimen A - AADvac1

NCT07167966
Conditions
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
Interventions
AADvac1, Donanemab
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Common Cold, Cough
Interventions
Robitussin Maximum Strength Cough and Chest Congestion DM, Robitussin Maximum Strength Nighttime Cough DM
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
Interventions
F-18 AV 1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
PPA, Non-fluent Aphasia, Apraxia of Speech, Primary Progressive Non-fluent Aphasia, Primary Progressive Aphasia
Interventions
AV-1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Niemann-Pick Disease, Type C
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

The Music, Sleep and Dementia Study

NCT04157244
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Tailored music listening intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Cognitive Assessment by BoCA

NCT04114994
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia, Parkinson Disease, Multiple Sclerosis, TBI
Interventions
Boston Cognitive Assessment (BoCA)
Diagnostic Test
Lead sponsor
Alzheimer's Light LLC
Industry
Eligibility
50 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Results available

SuperNOVA Clinical Stenting Trial

NCT01292928
Conditions
Atherosclerosis of Native Arteries of the Extremities, Unspecified
Interventions
Stent implantation
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
28
States / cities
Birminham, Alabama • Los Angeles, California • Atlanta, Georgia + 24 more
Conditions
Primary Progressive Aphasia
Interventions
tACS or multisensory stimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

NCT02676843
Conditions
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Tauopathies
Interventions
18F-AV-1451
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Conditions
Monocarboxylate Transporter 8 Deficiency, Allan-Herndon-Dudley Syndrome
Interventions
Tiratricol
Drug
Lead sponsor
Rare Thyroid Therapeutics International AB
Industry
Eligibility
Not listed
U.S. locations
17
States / cities
Birmingham, Alabama • Madera, California • San Diego, California + 13 more
Withdrawn No phase listed Observational Accepts healthy volunteers

A Composite MR Neuroimaging Marker for Alzheimer's Disease

NCT01615666
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
Interventions
memantine, Placebo pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 6 more
Conditions
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions
NIO752, Placebo
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
41 Years to 81 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 2 more
Not listed Not applicable Interventional Accepts healthy volunteers

Gamma-Induction in FrontoTemporal Dementia Trial

NCT04425148
Conditions
Frontotemporal Dementia
Interventions
Transcranial Alternating Current Stimulation (tACS), Sham Transcranial Alternating Current Stimulation (sham tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Inborn Errors of Metabolism

NCT00176904
Conditions
Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Gaucher's Disease, Fucosidosis, Wolman Disease, Niemann-Pick Disease, Batten Disease, GM1 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Sphingomyelin Lipidosis
Interventions
placebo (saline), Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
San Francisco, California • Decatur, Georgia • The Bronx, New York
Completed Not applicable Interventional Results available

Evaluation of the GORE TIGRIS Vascular Stent

NCT01576055
Conditions
Peripheral Arterial Disease
Interventions
TIGRIS Vascular Stent, BARD LifeStent
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
21 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
34
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oceanside, California + 30 more
Recruiting No phase listed Observational Accepts healthy volunteers

ALS Research Collaborative

NCT06885918
Conditions
Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
ALS Therapy Development Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Watertown, Massachusetts
Conditions
Niemann-Pick Disease, Type C
Interventions
N-Acetyl Cysteine
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Months and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Oakland, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Completed No phase listed Observational

Florbetaben PET Imaging in PPA

NCT04720001
Conditions
Primary Progressive Aphasia, Alzheimer Disease
Interventions
Florbetaben F18, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois